Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Urban Novak

Showing results (101-110 of 103) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 103 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE TrialMarco Ladetto, Katja Gutmair, Rita Tavarozzi, et al.
Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.
Blood|October 15, 2021
Genetic and phenotypic attributes of splenic marginal zone lymphomaFerdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, et al.
Pageof 11

Showing results (101-110 of 103) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 103 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE TrialMarco Ladetto, Katja Gutmair, Rita Tavarozzi, et al.
Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.
Blood|October 15, 2021
Genetic and phenotypic attributes of splenic marginal zone lymphomaFerdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, et al.
Pageof 11